- RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
This study is looking into a new medication called efruxifermin for people with a kind of liver disease called NASH/MASH and scarring (fibrosis). It's a large study where some people get the medication, and others get a dummy treatment, to see if it's safe and helps improve the liver condition.
For: NASH With Fibrosis · MASH With FibrosisUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
This study is testing a new medicine, Efruxifermin, for people with liver conditions like NAFLD/MASLD and NASH/MASH. We want to see if it's safe and how well it works compared to a dummy medicine.
For: NASH/MASH · NAFLD/MASLDUnited States · Argentina · Australia - RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This study is testing a new medicine, efruxifermin, for people with a serious liver condition called NASH/MASH cirrhosis. It's to see if the medicine helps improve liver health in those with scarring that hasn't yet caused severe problems.
For: NASH - Nonalcoholic Steatohepatitis · MASH - Metabolic Dysfunction-Associated SteatohepatitisUnited States · Argentina · Australia